Results 71 to 80 of about 84,964 (303)

DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia: Clinical Insights from a Real‐World Early Experience Program

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background DaxibotulinumtoxinA for injection (DAXI), a novel botulinum toxin (BoNT) formulated with a custom‐engineered peptide, was recently approved for treating cervical dystonia (CD). DAXI demonstrated a long duration of symptom relief in Phase 3 trials. Objective To report findings from PrevU, an early experience, real‐world observational
Laxman Bahroo, Aaron Ellenbogen, Robert A. Hauser, Han S. Lee, Peter McAllister, Atul T. Patel, Rashid Kazerooni, Todd M. Gross, Julia Sparrow, Conor J. Gallagher, David A. Hollander   +10 more
wiley   +1 more source

BOTOX injection to treat strabismus after infant botulism type B infection

American Journal of Ophthalmology Case Reports, 2020
Purpose: The significance of botulinum toxin to ophthalmologists is twofold. Botulism, a medical emergency, frequently presents with ocular findings including blurred vision, diplopia, ptosis, and photophobia as a result of the neurotoxin produced by ...
Sarah G. Bonaffini, Victoria Cocozza, Jing Jin   +2 more
doaj   +1 more source

Voice and Speech in Atypical Parkinsonian Disorders

Movement Disorders Clinical Practice, EarlyView.
Background Motor speech disorders are early, common, and functionally limiting features of atypical parkinsonian disorders (APDs) such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). These impairments are underrecognized and undertreated in neurology clinics.
Federico Rodriguez‐Porcel, Farwa Ali, Michiko Bruno, Heather Davis Cuevas, Rohit Dhall, Kylie Dunne‐Platero, Lawrence I. Golbe, Ihtsham Haq, Nicole Herndon, Lawrence S. Honig, Kyurim Kang, Sarah Kremen, Guillaume Lamotte, Nikolaus R. McFarland, Michela Mir, Leila Montaser‐Kouhsari, Alexander Pantelyat, Joel Page, Hylan Pickett, Laura Purcell Verdun, Kelly Richardson, Jessica Shurer, Michelle Troche, Rene L. Utianski, Katya Villarreal‐Cavazos, Tuhin Virmani, Anne‐Marie Wills, as the Diagnosis and Treatment Working Group, CurePSP Center of Care (CoC) Network, Farwa Ali, Michiko Bruno, Timothy Chang, Rohit Dhall, Kimiko Domoto‐Reilly, Lawrence I. Golbe, Ihtsham Haq, Lawrence S. Honig, Sarah Kremen, Guillaume Lamotte, Zoltan Mari, Nikolaus R. McFarland, Leila Montaser‐Kouhsari, Alexander Pantelyat, Federico Rodriguez‐Porcel, Junaid Siddiqui, Jessica Shurer, Christopher Spears, Tuhin Virmani, Anne‐Marie Wills   +48 more
wiley   +1 more source

Challenging the Clostridium botulinum toxin type A (BoNT/A) with a selection of microorganisms by culture methods and extended storage of used vials to assess the loss of sterility [PDF]

, 2015
In 2002, botulinum toxin type A (BoNT/A) was approved by the US Food and Drug Administration (FDA) for cosmetic use. However, there may be procedural differences between the ways in which a clinician handles, applies and stores the product compared to ...
Crean, Stjohn, Dennison, Sarah Rachel, Morton, Leslie Hugh Glyn, Singhrao, Simarjit Kaur, Turner, Martin   +4 more
core  

Psychiatric Comorbidity, Tic Severity and Quality of Life in Adults with Tourette's Syndrome

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Psychiatric comorbidities are common in adults with Tourette's Syndrome (TS), and appear to influence both tic severity and quality of life (QOL). Objective To assess the association between psychiatric comorbidities, tic severity and QOL in TS.
Andreas Hartmann, Christelle Nilles, Yulia Worbe, Davide Martino, Naoual Serari, Catherine Deans, Isabella Davenport, Julian Fletcher, Emmanuel Roze, Tamara Pringsheim   +9 more
wiley   +1 more source

Botulinum neurotoxin formulations: overcoming the confusion

Clinical, Cosmetic and Investigational Dermatology, 2018
Souphiyeh Samizadeh,1 Koenraad De Boulle2 1Great British Academy of Aesthetic Medicine, London, UK; 2Aalst Dermatology Clinic, Aalst, Belgium Abstract: Botulinum toxin A is produced by anaerobic spore-forming bacteria and is used for various therapeutic ...
Samizadeh S, De Boulle K
doaj  

An integrated, cost-effective efficient chain to deliver botulinum toxin in optimal conditions.

International Journal of Integrated Care, 2019
Introduction: Botulinum toxin is increasingly used in clinical care for a variety of conditions that include facial spasms, bleharospasms, and other abnormal movement disorders.
Marian Gomez Beldarrain, Amaia Santos Ibañez, Maria Carmen Maldonado Fernandez, Maria Jose Martinez Bengoechea, Juan Carlos Garcia-Monco   +4 more
doaj   +1 more source

Cluster of Botulism among dutch tourists in Turkey, june 2008 [PDF]

, 2010
In June 2008, three Dutch tourists participating in a mini-cruise in Turkey needed urgent repatriation for antitoxin treatment because of symptoms of botulism.
Ouwerkerk, M., van, Roest, H.I.J., Swaan, C.M.   +2 more
core   +1 more source

Achalasia: A review of Western and Iranian experiences [PDF]

, 2009
Achalasia is a primary motor disorder of the esophagus, in which esophageal emptying is impaired. Diagnosis of achalasia is based on clinical findings. The diagnosis is confirmed by radiographic, endoscopic, and manometric evaluations. Several treatments
Mikaeli, J., Islami, F., Malekzadeh, R.
core   +1 more source

Long-term efficacy of spasticity-corrective surgery and botulinum toxin injections for upper limb spasticity treatment

Journal of Rehabilitation Medicine - Clinical Communications
Objective: To evaluate the long-term efficacy of spasticity-corrective surgery and botulinum toxin treatment in patients with upper limb spasticity. Design: Pretest-posttest quasi-experimental study.
Therese Ramström, Johanna Wangdell, Carina Reinholdt, Trandur Ulfarsson, Lina Bunketorp Käll   +4 more
doaj   +1 more source